D R Sullivan1, C W Forsberg2, L Ganzini3, D H Au4, M K Gould5, D Provenzale6, K S Lyons7, C G Slatore8. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University, Portland, OR, United States; Health Services Research and Development, Veterans Affairs Portland Health Care System, Portland, OR, United States. Electronic address: sullivad@ohsu.edu. 2. Health Services Research and Development, Veterans Affairs Portland Health Care System, Portland, OR, United States. 3. Health Services Research and Development, Veterans Affairs Portland Health Care System, Portland, OR, United States; Division of Geriatric Psychiatry, Department of Psychiatry, Oregon Health and Science University, Portland, OR, United States. 4. Health Services Research and Development Service, Veterans Affairs Puget Sound Health Care System, and Department of Medicine, University of Washington, Seattle, WA, United States. 5. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States; Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. 6. VA Cooperative Studies Program Epidemiology Center-Durham, Durham VA Medical Center, and Duke University, Durham, NC, United States. 7. School of Nursing, Oregon Health and Science University, Portland, OR, United States. 8. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University, Portland, OR, United States; Health Services Research and Development, Veterans Affairs Portland Health Care System, Portland, OR, United States; Section of Pulmonary and Critical Care Medicine, Veterans Affairs Portland Health Care System, Portland, OR, United States.
Abstract
OBJECTIVES: Among lung cancer patients depression symptoms are common and impact outcomes. The aims of this study were to determine risk factors that contribute to persistent or new onset depression symptoms during lung cancer treatment, and examine interactions between depression symptoms and health domains that influence mortality. MATERIALS AND METHODS: Prospective observational study in five healthcare systems and 15 Veterans Affairs medical centers. Patients in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium with lung cancer were eligible. The 8-item Center for Epidemiologic Studies Depression (CES-D) scale was administered at baseline and follow-up. Scores ≥4 indicated elevated depressive symptoms. Health domains were measured using validated instruments. We applied logistic regression and Cox proportional hazards modeling to explore the association between depression symptoms, health domains, and mortality. RESULTS: Of 1790 participants, 38% had depression symptoms at baseline and among those still alive, 31% at follow-up. Risk factors for depression symptoms at follow-up included younger age (OR=2.81), female sex (OR=1.59), low income (OR=1.45), not being married (OR=1.74) and current smoking status (OR=1.80); high school education was associated with reduced odds of depression symptoms at follow-up, compared with lesser educational attainment (OR=0.74) (all p values <0.05). Patients with depression symptoms had worse health-related quality of life, vitality, cancer-specific symptoms, and social support than patients without depression symptoms (all p<0.001). The association between depression symptoms and increased mortality is greater among patients with more lung cancer symptoms (p=0.008) or less social support (p=0.04). CONCLUSIONS: Patient risk factors for depression symptoms at follow-up were identified and these subgroups should be targeted for enhanced surveillance. Patients with depression symptoms suffer across all health domains; however, only more lung cancer symptoms or less social support are associated with worse mortality among these patients. These potentially modifiable health domains suggest targets for possible intervention in future studies.
OBJECTIVES: Among lung cancerpatientsdepression symptoms are common and impact outcomes. The aims of this study were to determine risk factors that contribute to persistent or new onset depression symptoms during lung cancer treatment, and examine interactions between depression symptoms and health domains that influence mortality. MATERIALS AND METHODS: Prospective observational study in five healthcare systems and 15 Veterans Affairs medical centers. Patients in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium with lung cancer were eligible. The 8-item Center for Epidemiologic Studies Depression (CES-D) scale was administered at baseline and follow-up. Scores ≥4 indicated elevated depressive symptoms. Health domains were measured using validated instruments. We applied logistic regression and Cox proportional hazards modeling to explore the association between depression symptoms, health domains, and mortality. RESULTS: Of 1790 participants, 38% had depression symptoms at baseline and among those still alive, 31% at follow-up. Risk factors for depression symptoms at follow-up included younger age (OR=2.81), female sex (OR=1.59), low income (OR=1.45), not being married (OR=1.74) and current smoking status (OR=1.80); high school education was associated with reduced odds of depression symptoms at follow-up, compared with lesser educational attainment (OR=0.74) (all p values <0.05). Patients with depression symptoms had worse health-related quality of life, vitality, cancer-specific symptoms, and social support than patients without depression symptoms (all p<0.001). The association between depression symptoms and increased mortality is greater among patients with more lung cancer symptoms (p=0.008) or less social support (p=0.04). CONCLUSIONS:Patient risk factors for depression symptoms at follow-up were identified and these subgroups should be targeted for enhanced surveillance. Patients with depression symptoms suffer across all health domains; however, only more lung cancer symptoms or less social support are associated with worse mortality among these patients. These potentially modifiable health domains suggest targets for possible intervention in future studies.
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Alan R Teo; HwaJung Choi; Sarah B Andrea; Marcia Valenstein; Jason T Newsom; Steven K Dobscha; Kara Zivin Journal: J Am Geriatr Soc Date: 2015-10-06 Impact factor: 5.562
Authors: A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers Journal: Eur J Cancer Date: 2010-03-12 Impact factor: 9.162
Authors: Jeannine M Brant; Susan Beck; William N Dudley; Patrick Cobb; Ginette Pepper; Christine Miaskowski Journal: Cancer Nurs Date: 2011 Jan-Feb Impact factor: 2.592
Authors: Wayne A Bardwell; Loki Natarajan; Joel E Dimsdale; Cheryl L Rock; Joanne E Mortimer; Kathy Hollenbach; John P Pierce Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Christopher Fagundes; Desiree Jones; Elisabeth Vichaya; Charles Lu; Charles S Cleeland Journal: J Thorac Oncol Date: 2014-10 Impact factor: 15.609
Authors: Daniel C McFarland; Leah E Walsh; Rebecca Saracino; Christian J Nelson; William Breitbart; Barry Rosenfeld Journal: Palliat Support Care Date: 2021-06
Authors: Daniel C McFarland; Devika R Jutagir; Andrew H Miller; William Breitbart; Christian Nelson; Barry Rosenfeld Journal: J Natl Compr Canc Netw Date: 2020-04 Impact factor: 11.908
Authors: Cara L McDermott; Aasthaa Bansal; Scott D Ramsey; Gary H Lyman; Sean D Sullivan Journal: J Pain Symptom Manage Date: 2018-08-17 Impact factor: 3.612
Authors: Eleni M Rettig; Carole Fakhry; Russell K Hales; Flora Kisuule; Harry Quon; Ana P Kiess; Linda X Yin; Yuehan Zhang; Amanda L Blackford; M Bradley Drummond; Christine G Gourin; Wayne M Koch; David W Eisele; Gypsyamber D'Souza Journal: Head Neck Date: 2018-03-15 Impact factor: 3.147
Authors: Daniel C McFarland; Rebecca M Saracino; Andrew H Miller; William Breitbart; Barry Rosenfeld; Christian Nelson Journal: Future Oncol Date: 2020-12-11 Impact factor: 3.404